Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Acalabrutinib + AZD4573 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AZD4573 | AZD-4573|AZD 4573 | CDK9 Inhibitor 21 | AZD4573 is a selective inhibitor of Cdk9 that suppresses Mcl1 expression thus leads to apoptosis in tumor cells (Cancer Res 2018;78(13 Suppl):Abstract nr 310, PMID: 32175313, PMID: 31699827). | |
Acalabrutinib | Calquence | ACP-196 | BTK inhibitor 37 | Calquence (acalabrutinib) selectively inhibits BTK, resulting in decreased B-cell receptor signaling, and potentially leading to decreased tumor cell proliferation (PMID: 27903679, PMID: 26957112). Calquence (acalabrutinib) is FDA approved for use in patients with mantle cell lymphoma, chronic lymphocytic leukemia or small lymphocytic lymphoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04630756 | Phase Ib/II | Acalabrutinib + AZD4573 | AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer. | Active, not recruiting | USA | POL | IRL | GBR | FRA | ESP | CAN | AUS | 1 |